Pfizer COVID shot sales plummet after Trump administration ends universal recommendations

U.S. sales of Pfizer's Comirnaty shots have taken a nosedive since the Trump administration updated its immunization schedules last month and dropped the universal collective recommendations for COVID-19 vaccines.

The pharmaceutical company's revenues for the third quarter of 2025 are down 6% — amounting to a $1 billion drop — compared to the same stretch the previous year.

'CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks.'

Pfizer indicated in its latest earnings statement that "the operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.S. that reduced the eligible population for Comirnaty."

Sales of Comirnaty were down 25% in the United States, and sales of Paxlovid, an oral antiviral medication that treats mild-to-moderate COVID-19 in adults, were down 52%.

When his agency dropped the universal recommendation last month for Comirnaty — a controversial vaccine used at a time of population-wide immunity to treat an endemic virus fatal in roughly 1% of confirmed cases — Centers for Disease Control and Prevention Acting Director Jim O'Neill stated, "CDC's 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent. That changes today."

RELATED: Naomi Wolf continues to expose COVID vaccine: 'A depopulating technology'

Photo by PATRICK T. FALLON/AFP via Getty Images

The CDC's decision came just months after the U.S. Food and Drug Administration forced Pfizer to slap a damning warning on its Comirnaty vaccine noting the estimated unadjusted incidence of heart conditions following administration of the 2023-2024 formula of the shot, as well as the longitudinal results of a 2024 study concerning cardiac manifestations and outcomes of vaccine-associated myocarditis in American youths.

The FDA also required Pfizer to describe the new safety information in the adverse reactions section of its vaccine information insert such that it now notes that "the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age."

While the FDA has approved the drug for use in individuals who are 65 years of age and older or 5-64 years old who suffer from at least one underlying condition putting them at high risk for severe outcomes from COVID-19, it revoked the emergency use authorization for the shot in August.

Pfizer CEO Albert Bourla reportedly suggested on a Tuesday call with analysts that the company is looking for opportunities outside the United States, stating that the company's catalog of vaccines constitute a "key area of focus in international markets."

Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!